Biggest News Aggregation in the World
๐Ÿ“ฐ Immunic News

Page 16 - Immunic News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Immunic. Real-time updates on events, politics, business and more.

DGAP-News: Immunic, Inc. to Participate in Scientific, Investor and Industry Conferences in April

DGAP-News: Immunic, Inc. to Participate in Scientific, Investor and Industry Conferences in April Immunic, Inc. to Participate in Scientific, Investor and Industry Conferences in April 13.04.2021 / 12:30 Immunic, Inc. to Participate in Scientific, Investor and Industry Conferences in April NEW YORK, April 13, 2021 - Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and au...
United States Edna Kaplan Paula Schwartz Jessica Breu Robertj Fox Daniel Vitt

DGAP-News: Immunic, Inc. to Participate in Industry and Investor Conferences in March

DGAP-News: Immunic, Inc. to Participate in Industry and Investor Conferences in March Immunic, Inc. to Participate in Industry and Investor Conferences in March 02.03.2021 / 12:30 Immunic, Inc. to Participate in Industry and Investor Conferences in March NEW YORK, March 2, 2021 - Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced ma...
Edna Kaplan Paula Schwartz Jessica Breu Biocapital Europe Daniel Vitt Exchange Commission

Immunic, Inc. Announces Positive Top-Line Data From Investigator-Sponsored Phase 2 Proof-of-Concept Clinical Trial of IMU-838 in Primary Sclerosing Cholangitis

ย Immunic, Inc. (Nasdaq: IMUX), ย a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced positive top-line data from an investigator-sponsored phase 2 proof-of-concept clinical trial of IMU-838 in primary sclerosing cholangitis (PSC). This single-arm, open-label, exploratory study was designed to investigate IMU-838s potential to improve various biochemical parameters...
United States Paula Schwartz Edna Kaplan Keith Lindor Johne Eaton Daniel Vitt

Investegate |Immunic, Inc. Announcements | Immunic, Inc.: Immunic, Inc. Announces Positive Top-Line Data From Investigator-Sponsored Phase 2 Proof-of-Concept Clinical Trial of IMU-838 in Primary Sclerosing Cholangitis

Investegate announcements from Immunic, Inc., Immunic, Inc. Announces Positive Top-Line Data From Investigator-Sponsored Phase 2 Proof-of-Concept Clinical Trial of IMU-838 in Primary Sclerosing Cholangitis
United States Paula Schwartz Edna Kaplan Keith Lindor Johne Eaton Daniel Vitt

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News โ†’

DGAP-News: Immunic, Inc. Announces That Oral Treatment IMU-838 Shows Evidence of Clinical Activity in Moderate COVID-19 in Phase 2 CALVID-1 Trial

DGAP-News: Immunic, Inc. Announces That Oral Treatment IMU-838 Shows Evidence of Clinical Activity in Moderate COVID-19 in Phase 2 CALVID-1 Trial Table: IMU-838 Shows Acceleration of Time to Clinical Improvement High-risk patients and patients aged over 65 years experienced a more substantial treatment benefit from IMU-838 than in the general patient population: - The 75% probability [5] to reach clinical improvement (based on investigator assessment) was accelerated by 3.8 days in IMU-838 trea...
United States Paula Schwartz Edna Kaplan Jessica Breu Andreas Muehler Daniel Vitt

DGAP-News: Immunic, Inc. to Participate in the SVB Leerink 10th Annual Global Healthcare Conference on February 25

DGAP-News: Immunic, Inc. / Key word(s): Conference Immunic, Inc. to Participate in the SVB Leerink 10th Annual Global Healthcare Conference on February 25 11.02.2021 / 12:30 The issuer is solely responsible for the content of this announcement. Immunic, Inc. to Participate in the SVB Leerink 10t...
Edna Kaplan Jessica Breu Daniel Vitt Exchange Commission Rx Communications Group Immunic Inc

CNN CNN Tonight With Don Lemon October 19, 2019 02:55:00

Have destroyed all the defenses. they are defenseless and at the mer su of turkey and assad. this is exactly what turkey wanted. they wanted the curd on the defensive in a position where turkey could essentially engage in ethnic cleansing or genocide. if it wanted to. assad has them at their mercy as well. united states has been maintaining this buffer zone for the cuds and itself for five years. with a few hundred troops. extraordinarily strategic use of american power. pence went to turkey and...
Mer Su Of Turkey Turkey Wanted Butcher Assad Buffer Zone Ethnic Cleansing Mike Pence

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science